At Carolina Blood and Cancer Care Associates, the No One Left Alone (NOLA) initiative is working to break down cancer health disparities among its patients by addressing the social determinants of health that may be preventing equitable access to care.
At Carolina Blood and Cancer Care Associates, where Sashi Naidu, MD, is director of research, the No One Left Alone (NOLA) initiative, first implemented in January 2021, is working to break down cancer health disparities among its patients by addressing the social determinants of health that may be preventing their equitable access to care.
Transcript
Can you discuss the NOLA initiative from Carolina Blood and Cancer Care Associates?
NOLA was conceived by our need at our practice. There are a lot of foundations and opportunities for patient access, but it’s often a fragmented process. So the purpose of NOLA was to bring that process in house, where the patients can feel comfortable that the physicians who are their treating doctors are taking care of this aspect of their health care, which often can be a very big challenge—even sometimes more than the clinical aspects of their cancer care.
What is the status of patient assistance initiatives for oral cancer drugs within NOLA?
We picked up oral financial assistance initiatives just like the intravenous drugs. It’s a seamless process. As with many community oncology practices, there is an oral dispensary in house. It is a just a very easy transition to add oral financial assistance to our intravenous drug financial assistance. So there’s not been any major problems there.
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More